Laatste proeven

EudraCT Number: 2022-001476-33

Sponsor Protocol Number: D5985C00003

Start Date: 2022-11-02

Sponsor Name: AstraZeneca AB

Full Title: A Randomized, Double-Blind, 12-Week (with an Extension to 52 weeks in a subset of Participants), Multi-Center Study to Assess the Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF)...

Medical condition: Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	100000004855	10010952	COPD	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: BG (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-000253-92

Sponsor Protocol Number: EHP-101-MS02

Start Date: 2022-10-14

Sponsor Name: Emerald Health Pharmaceuticals Inc.

Full Title: A Phase IIa, Open-label, Multicentre Dose-Finding Trial in Patients with Relapsing Forms of Multiple Sclerosis (RMS) to Evaluate the Safety, Tolerability and Preliminary Efficacy of EHP-101

Medical condition: Relapsing Forms of Multiple Sclerosis (RMS)

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.0	10029205 - Nervous system disorders	10080700	Relapsing multiple sclerosis	PT
	21.1	10029205 - Nervous system disorders	10063400	Secondary progressive multiple sclerosis	PT
	21.1	10029205 - Nervous system disorders	10063399	Relapsing-remitting multiple sclerosis	PT

Population Age: Adults

Gender: Male, Female

Trial protocol: ES (Ongoing)

Trial results: (No results available)

EudraCT Number: 2021-002905-89

Sponsor Protocol Number: 20186

Start Date: 2022-10-06

Sponsor Name: Bayer AG

Full Title: An 18-month, open-label, single-arm safety extension study of an age-and bodyweight-adjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children and young adults f...

Medical condition: Treatment of children with chronic kidney disease and proteinuria

Disease:	Version	SOC Term	Classification Code	Term	Level
	23.1	10038359 - Renal and urinary disorders	10064848	Chronic kidney disease	PT
	20.1	10038359 - Renal and urinary disorders	10037032	Proteinuria	PT

Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: ES (Ongoing) BE (Ongoing) NL (Ongoing) AT (Ongoing) DK (Ongoing)

Trial results: (No results available)

EudraCT Number: 2020-006072-32

Sponsor Protocol Number: 2019/ABM/01/00078

Start Date: 2022-10-05

Sponsor Name: Heliodor Święcicki Clinical Hospital of the Poznań University of Medical Sciences

Full Title: Pulmonary REsistance modification under treatment with Sacubitil/valsartaN in paTients with HeartFailure with reduced ejection fraction

Medical condition: Heart Failure with reduced ejection fraction.

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	100000004849	10078289	Heart failure with reduced ejection fraction	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: PL (Ongoing)

Trial results: (No results available)

EudraCT Number: 2021-006326-48

Sponsor Protocol Number: CO43810

Start Date: 2022-09-27

Sponsor Name: Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd

Full Title: A PHASE I/II, OPEN-LABEL, SINGLE-ARM, TWO-PART TRIAL TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF GLOFITAMAB IN COMBINATION WITH CHEMOIMMUNOTHERAPY IN PEDIATRIC AN...

Medical condition: CD20 positive B-Cell Non-Hodgkin Lymphoma

Disease:	Version	SOC Term	Classification Code	Term	Level
	23.1	100000004864	10084346	B-cell non-Hodgkin's lymphoma	LLT

Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: ES (Ongoing) DK (Ongoing) DE (Ongoing)

Trial results: (No results available)

EudraCT Number: 2021-003087-27

Sponsor Protocol Number: ARGX-113-2009

Start Date: 2022-09-26

Sponsor Name: argenx BV

Full Title: A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid

Medical condition: Bullous Pemphigoid

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	100000004858	10006567	Bullous pemphigoid	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Ongoing) HU (Ongoing) ES (Ongoing) GR (Ongoing) BG (Ongoing) NL (Ongoing) HR (Ongoing)

Trial results: (No results available)

EudraCT Number: 2021-003380-95

Sponsor Protocol Number: CDYP688A12101

Start Date: 2022-09-20

Sponsor Name: Novartis Pharma AG

Full Title: A Phase I/II, multi-center, open label study of DYP688 in patients with metastatic uveal melanoma (MUM) and other GNAQ/11 mutant melanomas

Medical condition: MUM and other non-uveal, GNAQ/11 mutant melanomas

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10081431	Uveal melanoma	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10027481	Metastatic melanoma	LLT
	20.0	100000004853	10030052	Ocular melanomas	HLT

Population Age: Adolescents, Under 18, Adults, Elderly

Gender: Male, Female

Trial protocol: NL (Ongoing)

Trial results: (No results available)

EudraCT Number: 2021-005504-36

Sponsor Protocol Number: ABNCoV2-03

Start Date: 2022-09-19

Sponsor Name: Bavarian Nordic A/S

Full Title: Evaluation of the Immunogenicity, Safety, and Tolerability of a Single Dose of ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2: a Phase 3 Trial in Two Parts—Randomized, Doubl...

Medical condition: COVID-19 disease

Disease:	Version	SOC Term	Classification Code	Term	Level
	23.1	10042613 - Surgical and medical procedures	10084457	COVID-19 immunisation	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DK (Ongoing) BE (Ongoing)

Trial results: (No results available)

EudraCT Number: 2021-005071-40

Sponsor Protocol Number: AVT03-GL-C01

Start Date: 2022-09-05

Sponsor Name: Alvotech Swiss AG

Full Title: A Randomized, Double-Blind, Parallel Design, Repeat Dose, 2-arm, Multicenter Study Comparing the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profiles of AVT03 and US-Prolia® in Postmenopa...

Medical condition: Osteoporosis

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10028395 - Musculoskeletal and connective tissue disorders	10031282	Osteoporosis	PT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: BG (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-000271-39

Sponsor Protocol Number: 2022-01

Start Date: 2022-09-02

Sponsor Name: Adeptio Pharmaceuticals Ltd

Full Title: Single-arm, open-label dose titration phase 2 clinical trial of (+)-α-DHTBZ for the treatment of tardive dyskinesia (TD)

Medical condition: Tardive dyskinesia

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	10029205 - Nervous system disorders	10043118	Tardive dyskinesia	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: HR (Ongoing)

Trial results: (No results available)

Laatste proeven

Medische omstandigheden

Sponsors en medewerkers

Geneesmiddelinterventies